Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • ICR

    - PMLiVE

    Lilly’s Omvoh shows improved outcomes in ulcerative colitis

    The phase 3 trial results demonstrated improved symptomatic, clinical and quality-of-life measures

    - PMLiVE

    Abivax shares positive late-stage results for obefazimod in ulcerative colitis

    Inflammatory bowel disease affects nearly one in every 100 people in the US

    - PMLiVE

    J&J’s Tremfya approved by MHRA to treat Crohn’s disease and ulcerative colitis

    Inflammatory bowel disease is estimated to affect more than 500,000 people in the UK

    - PMLiVE

    Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis

    More than 2.5 million people in Europe are affected by the inflammatory bowel disease

    - PMLiVE

    Johnson & Johnson’s Tremfya granted EC approval to treat ulcerative colitis in adults

    More than 2.5 million people in Europe are living with the inflammatory bowel disease

    - PMLiVE

    J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients

    Approximately 25% of cases are diagnosed during childhood or adolescence

    - PMLiVE

    Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease

    Inflammatory bowel disease is estimated to affect nearly two million people across Europe

    - PMLiVE

    Johnson & Johnson’s Tremfya granted FDA approval to treat Crohn’s disease

    An estimated three million people in the US are affected by inflammatory bowel disease

    - PMLiVE

    J&J receives three CHMP recommendations for immunology and oncology indications

    Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively

    - PMLiVE

    J&J’s shares positive results for subcutaneous Tremfya in phase 3 ulcerative colitis trial

    Inflammatory bowel disease affects almost one in every 100 people in the US

    - PMLiVE

    Eli Lilly shares two-year results for Omvoh in active Crohn’s disease patients

    Inflammatory bowel disease affects almost one in every 100 people in the US

    - PMLiVE

    ICR researchers uncover new method for predicting bowel cancer risk in IBD patients

    Approximately 500,000 people in the UK are affected by Crohn’s disease or ulcerative colitis

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links